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Doxorubicin Selectively Inhibits Brain Versus Atrial
Natriuretic Peptide Gene Expression in Cultured
Neonatal Rat Myocytes
Songcang Chen, Miklos Garami, David G. Gardner
Abstract—Doxorubicin is an antineoplastic agent with significant cardiotoxicity. We examined the effects of this agent on
the expression of the natriuretic peptide (NP) genes in cultured neonatal rat atrial myocytes. Doxorubicin suppressed NP
secretion, steady-state NP mRNA levels, and NP gene promoter activity. In each instance, brain NP (BNP) proved to
be more sensitive than atrial NP (ANP) to the inhibitory effects of the drug. ICRF-187 and probucol reversed the
inhibition by doxorubicin of ANP mRNA accumulation and ANP gene promoter activity while exerting no effect on
BNP mRNA levels or promoter activity. This represents the first identification of the NP genes as targets of doxorubicin
toxicity in the myocardial cell. This inhibition operates predominantly at a transcriptional locus and has more potent
effects on BNP versus ANP secretion/gene expression. Measurement of BNP secretion/gene expression may provide a
sensitive marker of early doxorubicin cardiotoxicity. (Hypertension. 1999;34:1223-1231.)
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Doxorubicin is an anthracycline antibiotic that is usedclinically in the management of a variety of leukemias
and solid tumors.1 Despite its potent antineoplastic activity,
its use is limited by the dose-related cardiotoxicity associated
with the drug. This toxicity is characterized by progressive
myocyte damage that can lead to dilated cardiomyopathy and
refractory congestive heart failure.2
The mechanisms that underlie the cardiotoxicity are only
partially understood. Possible mechanisms include direct or
indirect release of endogenous toxins (eg, histamine),3 alter-
ations in intracellular calcium homeostasis,4 generation of
free radicals that damage cellular membranes,5,6 and interca-
lation of drug in the nuclear and mitochondrial genome,
resulting in diminished RNA and protein synthesis.7 Of these
mechanisms, the free radical hypothesis has received the most
support. It is thought that doxorubicin, through its semiqui-
none metabolite, generates superoxide anion and superhy-
droxide free radicals by using intracellular iron as a cofactor.8
Because the heart is relatively deficient in those enzymes
responsible for clearing free radicals (ie, superoxide dis-
mutase, catalase, and glutathione peroxidase),6 the adminis-
tration of doxorubicin may lead to significant lipid peroxida-
tion and destruction of mitochondrial membranes.
Dexrazoxane (ICRF-187),9 a chelator of intracellular iron,
and probucol,10 an antioxidant with hypolipidemic properties,
have each been shown to offer protection against the cardio-
myopathic properties of doxorubicin in animal and selected
human studies. However, neither dexrazoxane nor probucol
offers complete protection from the cardiomyopathic effects
of doxorubicin.10 Thus, a more detailed understanding of the
mechanisms underlying this toxicity may lead to better
methods for early detection of cardiac dysfunction and the
design of effective therapeutic strategies to limit its
progression.
Atrial natriuretic peptide (ANP) and brain natriuretic pep-
tide (BNP) are hormones that are produced and secreted
predominantly from the myocytes of the heart. ANP is
preferentially expressed in the atrium but is found at low
levels in adult ventricular myocytes.11 BNP is more uniformly
distributed between atrial and ventricular myocardium.12 The
expression of both ANP and BNP genes is activated early in
the process of myocyte hypertrophy. The high degree of
fidelity with which this activation occurs has led to their use
as markers of the hypertrophic process in a variety of in
vitro,13,14 whole-animal,15 and clinical16 models.
Bauch et al17 reported elevations of plasma ANP in
pediatric patients 3 to 5 weeks after doxorubicin treatment. A
more detailed animal study from Bernardini et al18 found an
acute reduction in plasma ANP levels after treatment of intact
female Wistar rats with a single dose of doxorubicin. Thus,
the nature of the effect of doxorubicin on ANP gene expres-
sion and secretion is poorly defined, and effects on BNP
expression have yet to be reported. We have used an in vitro
model of cultured neonatal rat atrial myocytes to study the
effect of doxorubicin on the expression of the natriuretic
peptide (NP) genes. Our findings suggest that doxorubicin
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inhibits the secretion and expression of both genes, albeit
with different levels of effectiveness.
Methods
Cell Culture
Atrial myocyte–enriched cultures were generated from the upper one
third of 1-day-old neonatal rat hearts by alternate cycles of trypsin
digestion and mechanical disruption as previously described.19 Cells
were cultured in DMEM containing 10% enriched calf serum (ECS,
Gemini Bioproducts), 2 mmol/L glutamine, 131025 U/L penicillin,
and 100 g/L streptomycin for 48 hours before switching to serum
substitute (SS) medium.20
Cell Viability Bioassay
Cell viability in the atrial myocyte cultures was measured by use of
the Celltiter 96 AQueous Non-Radioactive Cell Proliferation Assay kit
(Promega). Atrial cells were cultured in 96-well plates at a density of
33104 cells per well for 48 hours before changing to DMEM/SS.
Cells were then treated with different concentrations of doxorubicin
for 24 hours or 0.3 mmol/L doxorubicin (Sigma Chemical Co) for
variable periods of time. Tetrazolium compound was added to each
well according to the instructions provided by Promega and then
incubated for 2 to 4 hours at 37°C in a humidified 5% CO2
atmosphere. Absorbance at 490 nm was recorded by an ELISA plate
reader (Microplate, EL 310, Bio-Tek Instruments).
Radioimmunoassay
Atrial cells were plated in 24-well dishes at a density of 105 cells per
well and cultured in DMEM/ECS for 48 hours. At that point, all cells
were placed in DMEM/SS and treated with different concentrations
of doxorubicin for 24 hours or 0.3 mmol/L doxorubicin for varying
periods of time. The culture medium of each well was collected,
centrifuged to remove cellular debris, and frozen at 270°C until
assayed. Radioimmunoassay was performed with the use of a
commercial kit (Peninsula Laboratories) according to the instruc-
tions provided by the manufacturer.
Northern Blot Analysis
Atrial cells were cultured in DMEM/ECS for 48 hours, changed to
DMEM/SS, and then challenged with the agents indicated for
different time intervals. Total RNA was isolated from cells with the
RNeasy mini kit (Qiagen, Inc) according to the instructions provided
by the manufacturer. RNA (8 to 10 mg) was separated on a gel that
contained 2.2% formaldehyde, transferred to a nitrocellulose filter,
and hybridized with a 640-bp fragment of the rat BNP cDNA. The
blots were subsequently stripped of probe and rehybridized with an
840-bp fragment of the rat ANP cDNA. To normalize the blots for
differences in RNA loading and/or transfer to the membranes, the
blots were stripped a second time and rehybridized with a 1.3-kb
GAPDH cDNA probe. Autoradiographic signals were quantified by
use of the NIH Image program. For measurement of mRNA stability,
cells were cultured in DMEM/SS with 5 mg/L actinomycin D (Act
D, Calbiochem-Novachem) alone or 5 mg/L Act D plus 0.3 mmol/L
doxorubicin, in the presence or absence of 20 mmol/L probucol
(Sigma), for varying periods of time. Cells were collected, and total
RNA was isolated. ANP and BNP mRNAs were detected and
normalized for expression of the GAPDH transcript as described
above. Results are expressed as percent of this normalized ratio at
zero time in the absence of additions.
DNA Transfection and CAT and
Luciferase Assays
Cells were transfected on the day of isolation with 20 mg of 2109
thymidine kinase (TK) promoter–driven chloramphenicol acetyl-
transferase (CAT),21 2 mg of 21595 human BNP (hBNP)-
luciferase,22 or 2 mg of 22593 human ANP (hANP)-luciferase
(22593 to 118 relative to the transcription start site in hANP gene,
linked to luciferase reporter in pMG-1). Transient transfection was
performed as described previously.22 After 48 hours, media was
changed to DMEM/SS that contained doxorubicin or other agents, as
indicated, and the incubations were continued for varying periods of
time. Cells were then collected, and lysates were generated as
described previously.22 Equal amounts of extract protein were
processed for measurement of luciferase or CAT activity.
[H]Uridine Incorporation
Cells were cultured in DMEM/ECS in 24-well plates for 48 hours. At
that point, all cells were placed in DMEM/SS and treated with 5
mg/L Act D for defined periods of time. To determine effects on new
RNA synthesis, cells were pulsed with 2 mCi/L [5,6-3H]uridine
(NEN Research Products) in minimal Eagle’s medium (MEM) with
Earle’s balanced salt solution (EBSS) containing the same additives
for the last 4 hours of the incubation. Cells were then washed 3 times
with PBS and treated with 10% trichloroacetic acid for 30 minutes at
4°C. Cellular residues were rinsed in 95% ethanol, solubilized in
0.25N NaOH at 4°C for 2 hours, and then neutralized with 2.5 mol/L
HCl/1 mol/L Tris HCl (pH 7.5). Incorporated radioactivity was
determined by scintillation counting.
To assess nascent RNA stability, atrial cells were grown in
DMEM/ECS in 24-well dishes for 48 hours. At that point, cells were
pulsed with 2 mCi/L [3H]uridine in MEM/EBSS for 4 hours. After
incubation, the media was discarded, and cells were washed 4 times
with PBS and cultured in DMEM/SS containing 0.1 mmol/L unla-
beled uridine, in the presence or absence of 5 mg/L Act D,
0.3 mmol/L doxorubicin, or 20 mmol/L probucol, for 4, 8, or 24
hours. At each time point, cells were washed 3 times with PBS, and
[3H]uridine incorporation was assayed according to the protocol
described above.
Statistical Analysis
Data are presented as mean6SD. Statistical analysis was performed
by using 1-way ANOVA and the Newman-Keuls test for
significance.
Results
Doxorubicin is known to be toxic to cultured cardiac myo-
cytes, particularly at higher concentrations.23 Because we
were interested in looking at gene expression in viable
myocytes rather than decay of transcriptional activity in
Effect of Dox on Atrial Cell Viability
% Control
Dox, mmol/L
0 10066.8
0.003 97.063.9
0.03 94.867.7
0.3 90.763.7
3 39.564.8*
Time, h
0 10065.3
3 94.168.7
6 96.465.8
12 94.867.4
24 89.364.9
48 35.564.6*
Values are mean6SD from 3 different experiments. Atrial myocytes were
plated in 96-well dishes at a density of 33104 cells/well. After cells were
cultured for 48 hours, they were treated with Dox at the indicated concentration
for 24 hours or 0.3 mmol/L Dox for the time indicated. Cell viability based on
absorbance (490 nm) was measured by cell proliferation assay.
*P,0.01 vs control.
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premorbid cells, we examined the viability of cells in our
atrial myocyte cultures as a function of doxorubicin concen-
tration and duration of treatment. As shown in the Table, cell
viability was well preserved with doses of doxorubicin as
high as 0.3 mmol/L for periods as long as 24 hours ('90%
viability), whereas higher concentrations of doxorubicin
(3 mmol/L) or longer exposure times (48 hours) led to a
precipitous decrease in the number of viable cells in the
cultures. For all subsequent experiments, doxorubicin was
used at a maximal concentration of 0.3 mmol/L for no longer
than 24 hours. This dose range and duration of exposure have
been shown to selectively inhibit muscle gene expression in
the cardiac myocytes.23
We examined the effect of doxorubicin on the secretion of
immunoreactive (ir) ANP and BNP in these cultures. As
shown in Figure 1A, doxorubicin effected a dose-dependent
decrease in irNP release from the atrial myocytes. Notewor-
thy, however, the inhibition was considerably more effective
for irBNP (maximal inhibition, 90% at 0.3 mmol/L doxoru-
bicin) than for irANP (maximal inhibition, 50% under the
same conditions), implying greater sensitivity of BNP versus
ANP to the inhibitory effects of this drug. Differential
sensitivity to doxorubicin was also seen in an abbreviated
time-course experiment presented in Figure 1B. Inhibition of
irBNP secretion was first seen at 6 hours (versus 24 hours for
irANP), whereas maximal inhibition after 24 hours of expo-
sure to the drug was '90% for irBNP and '60% for irANP.
Similar findings were noted at the level of NP gene
expression. As shown in Figures 2A and 2B, steady-state
levels of BNP mRNA were considerably more sensitive to the
inhibitory effects of doxorubicin than were those of ANP.
Maximal inhibition (ie, that seen at 0.3 mmol/L doxorubicin)
was once again '90% for BNP and '60% for ANP. Levels
of the GAPDH mRNA were unaffected by treatment with the
drug. The kinetics of the fall in NP mRNA levels were similar
to those seen at the level of secretion (Figures 2C and 2D).
BNP mRNA levels were reduced by 50% after as little as 6
hours of exposure to doxorubicin and were near maximally
suppressed after 24 hours, whereas inhibition of ANP mRNA
levels ('60% inhibition) was seen only after 24 hours of drug
exposure.
The inhibition of steady-state NP gene transcript levels was
mirrored at the level of promoter activity. Doxorubicin
treatment of atrial myocytes transfected with either ANP or
BNP gene promoter–driven luciferase reporters resulted in a
dose-dependent (Figure 3A) and time-dependent (Figure 3B)
decrease in reporter activity, implying that the inhibitory
effects of doxorubicin operate, at least in part, at a transcrip-
tional locus. These effects are not exerted on all promoters.
Doxorubicin treatment of atrial myocytes transfected with a
TK promoter–driven CAT reporter did not result in a signif-
icant reduction in reporter activity (data not shown). Note-
worthy, the effects of the drug on ANP and BNP promoter
activity were much more equivalent than the effects of the
drug on their respective mRNA levels.
We next examined the ability of ICRF-187 (Pharmacia,
Inc) to prevent the doxorubicin-dependent reduction in NP
gene expression. As shown in Figure 4A and 4B, ICRF alone
effected a modest increase in ANP mRNA levels. It led to an
even more pronounced increase in those cultures treated with
doxorubicin (ie, reversal of the doxorubicin-dependent reduc-
tion in ANP mRNA levels); however, ICRF had no effect on
steady-state BNP mRNA levels, either in the presence or
absence of doxorubicin. Preincubation of the cultures with
ICRF for 2 hours did not amplify the effect on ANP mRNA
levels when those cultures were compared with samples to
which doxorubicin and ICRF had been added simultaneously,
nor did it restore BNP gene expression.
There was a similar ICRF-dependent increase in ANP gene
promoter activity (Figure 4C), either in the presence or
absence of doxorubicin, although the magnitude of the effect
(ie, fold induction) was considerably larger in the presence of
the drug. ICRF failed to restore BNP gene promoter activity
after doxorubicin treatment, implying selectivity in the re-
sponse. We assume that the increase in ANP gene promoter
activity accounts, at least in part, for the recovery of ANP
mRNA levels.
Similar analyses were performed by using the antioxidant
probucol. Unlike ICRF, probucol alone had little effect on
Figure 1. Doxorubicin decreases BNP and ANP secretion in
dose- and time-dependent fashion. Atrial cells were cultured for
48 hours. At that point, cells were placed in DMEM/SS and
treated with different concentrations of doxorubicin for 24 hours
(A) or 0.3 mmol/L doxorubicin for varying periods of time (B).
Culture medium was collected and subjected to radioimmuno-
assay. Control activity was determined in parallel untreated cul-
tures in this figure (BNP, 7.360.68 ng/L per hour; ANP,
32.964.1 ng/L per hour) and in all subsequent figures. Data rep-
resent the mean6SD from 3 different experiments. 1P,0.05,
*P,0.01 vs control.
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either ANP or BNP mRNA levels (Figures 5A and 5B);
however, it effected a near-complete recovery of
doxorubicin-suppressed ANP transcript levels. The highest
concentration of probucol effected only a modest increase in
doxorubicin-suppressed BNP mRNA levels.
Probucol alone had no effect on either ANP or BNP gene
promoter activity; however, like ICRF, it partially reversed
doxorubicin-dependent suppression of the ANP, but not BNP,
promoter (Figure 5C). The combination of ICRF and probu-
col together had no greater effect than that seen with probucol
alone. It should be noted, however, that probucol, in the
presence of doxorubicin, increased ANP gene promoter
activity to only a fraction of that seen in the control cultures,
whereas ANP mRNA levels approached those of the control
cultures at higher probucol concentrations (Figure 5A), im-
plying enhanced stability of the ANP transcript in the
presence of the antioxidant.
To examine this latter question in greater detail, we used
Act D to suspend RNA synthesis in our atrial myocyte
cultures and followed the decay of ANP or BNP mRNA
levels in the presence or absence of probucol. At the concen-
tration used in the present study, Act D reduced [3H]uridine
incorporation by .95% at 5 hours and by .99% after 24
hours of incubation (data not shown), indicating adequate
inhibition of transcription. As shown in Figures 6A and 6B,
the half-life of the native ANP gene transcript is in the range
of 24 hours, whereas that for the BNP transcript is '4 to 5
hours, supporting the previously reported differential tran-
script stability for these 2 gene products.24 Of note, the
inclusion of probucol in the incubation led to a significant
stabilization of the ANP transcript (half-life .24 hours) but
had no effect on the BNP transcript. In the presence of
doxorubicin, BNP transcripts tended to be more stable than in
the absence of the drug (Figures 6C and 6D). In this setting,
Figure 2. Doxorubicin effects a dose- and time-dependent reduction in both BNP and ANP mRNA levels. Cells were cultured and
treated as described in Figure 1. Total RNA was isolated from cells. RNA (8 to 10 mg) was size-fractionated, transferred to a nitrocellu-
lose filter, and sequentially blot-hybridized with radiolabeled cDNAs for BNP, ANP, and GAPDH. Representative experiments are pre-
sented in A and C. Pooled data (n54) are shown as normalized BNP/GAPDH or ANP/GAPDH mRNA ratios in B and D. 1P,0.05,
*P,0.01 vs control.
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probucol had a modest stabilizing effect on the BNP mRNA.
The ANP transcript half-life was not significantly affected by
inclusion of doxorubicin; however, the addition of probucol
led to enhanced stability of the transcript in both settings.
Collectively, these data indicate that probucol reverses
doxorubicin-dependent suppression of ANP gene expres-
sion by increasing transcriptional activity of the gene (ie,
by preventing doxorubicin-dependent suppression of ANP
gene transcription) and by effecting a stabilization of the
ANP mRNA in doxorubicin-independent fashion. Probucol
failed to protect BNP gene transcription and afforded only
a modest increase in transcript stability in the presence of
doxorubicin. It is the latter effect, presumably, that ac-
counts for the slight increase in steady-state BNP transcript
levels seen in Figure 5.
To determine whether the effects of probucol and/or
doxorubicin could be extrapolated to a more general RNA
population in these cells, we pulsed cells with [3H]uridine for
4 hours, then washed them free of the label, and added
unlabeled uridine (0.1 mmol/L) and Act D, in the presence or
absence of doxorubicin and/or probucol, for different time
intervals. Measurements of [3H]uridine incorporation at dif-
Figure 3. Dose- and time-dependent inhibition of BNP and ANP
promoter activity by doxorubicin. Cells were transfected with 2
mg of 21595 hBNP- luciferase or 22593 hANP- luciferase
reporter. After transfection, cells were cultured and treated as
described in Figure 1. Cells were then collected for measure-
ment of luciferase activity. Data presented were obtained from 4
independent experiments. Dose dependence of the doxorubicin
effect is presented in A. The time course of the response is pro-
vided in B. 1P,0.05, *P,0.01 vs control.
Figure 4. Effect of ICRF-187 on basal and doxorubicin-inhibited
BNP and ANP mRNA levels and promoter activities. Cells were
exposed to the indicated concentrations of ICRF, with or with-
out 0.3 mmol/L doxorubicin (Dox), for 24 hours. In a single
group, cells were preincubated with 6 mmol/L ICRF for 2 hours
before the addition of 0.3 mmol/L Dox for 24 hours. BNP and
ANP mRNAs were detected as described in Figure 2. Represen-
tative experiments are shown in A. Pooled data (n54) are pre-
sented in B. In separate experiments, atrial cells were trans-
fected with hBNP-luciferase and hANP-luciferase. Forty-eight
hours after transfection, cells were treated as above, cultured
for 24 hours, and harvested for luciferase assay. Data are
derived from 5 independent experiments (C). #P,0.05, *P,0.01
vs control; 1P,0.01 vs Dox alone.
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ferent time points during the “chase” period provide assess-
ments of the time-dependent stability of the nascently labeled
RNA population. As shown in Figure 7, after suspension of
RNA synthesis by Act D, 3H-RNA levels decayed by '50%
after 4 hours and by .75% after 24 hours. Probucol alone had
no effect on the level of [3H]uridine incorporation but did
promote a modest increment above that seen in the presence
of Act D that was statistically significant at 8 and 24 hours,
implying that probucol has a modest stabilizing effect on this
newly synthesized RNA population. Doxorubicin treatment
also led to a decrease in 3H-RNA levels over time, but this
decrease was not additive with that produced by Act D,
implying that doxorubicin, like Act D, acts predominantly at
the level of RNA synthesis and has little additional destabi-
lizing effect on existing transcripts. Probucol partially re-
versed the decrease in 3H-RNA levels seen with doxorubicin
treatment at 8 and 24 hours, presumably reflecting a combi-
nation of mRNA stabilization with or without recovery of
doxorubicin-suppressed RNA synthesis.
Discussion
The present study provides the first report of selective
inhibition of NP gene expression by doxorubicin in cardiac
myocytes. This inhibition was demonstrated under conditions
that did not affect the viability of the cell population under
study. The important findings presented here are as follows:
(1) ANP and BNP secretion, steady-state mRNA levels, and
gene promoter activity are suppressed by doxorubicin treat-
ment. Particularly noteworthy, BNP appears to be uniquely
sensitive to the effects of this drug. (2) Both ICRF and
probucol, putative antagonists of doxorubicin cardiotoxicity,
restore steady-state levels of ANP mRNA to near control
levels yet display a much more modest effect in reversing the
inhibition of ANP gene promoter activity. (3) Neither ICRF
nor probucol has a major impact on doxorubicin-dependent
reductions in BNP mRNA levels or promoter activity.
(4) Probucol appears to have a stabilizing effect on transcripts
in atrial myocytes. This is most marked for the ANP gene
transcript, less marked for a newly synthesized RNA popu-
lation, and quite limited for the BNP transcript. (5) The
inhibitory activity of doxorubicin appears to operate predom-
inantly at the level of new RNA synthesis. There is no
decrease in NP mRNA stability in the presence of doxorubi-
cin; in fact, the BNP mRNA appears to be more stable in the
presence of the drug.
It has been reported previously that doxorubicin targets the
expression of specific genes in promoting its myocardio-
pathic effects. These include genes involved in sarcomeric
function,23,25 like a-actin, troponin I, and myosin light chain
2, as well as a number of genes involved in ATP production,26
including a heart- and muscle-specific isoform of ADP/ATP
translocase, the Reiske iron-sulfur protein (a ubiquitously
expressed electron transport chain component), and a muscle
isozyme of phosphofructokinase. The precise molecular
mechanism underlying this inhibition of gene transcription is
unknown but has been suggested to be linked to a reduction
of myoD activity27; however, studies from Evans et al28
indicate that overexpression of Id, a suppressor of myoD
activity, in cardiac myocytes does not result in significant
Figure 5. Effect of probucol (Prob) on basal and Dox-inhibited
BNP and ANP transcript levels and promoter activities. Cells
were treated with the indicated concentrations of probucol, with
or without 0.3 mmol/L Dox, for 24 hours. BNP and ANP mRNAs
were measured as described in Figure 2. Representative autora-
diographs are shown in A. Pooled data from 3 independent
experiments are presented in B. In separate experiments, cells
were transfected with hANP-luciferase or hBNP-luciferase.
Forty-eight hours later, cells were incubated with probucol in
the presence or absence of Dox for 24 hours before measure-
ment of luciferase activity. Pooled data are presented from 4
separate experiments (C). **P,0.05, *P,0.01 vs control;
#P,0.05, 1P,0.01 vs Dox alone.
1228 Hypertension December 1999
 at SEMMELWEIS UNIV OF MED (B13/62 on August 2, 2007 hyper.ahajournals.orgDownloaded from 
suppression of the ANP gene promoter, implying that the
mechanism underlying doxorubicin-dependent inhibition of
this gene may be distinct from that governing inhibition of
other myogenic proteins.
Our analysis identifies 2 cardiac-specific genes encoding
secretory products (ANP and BNP) whose expression is
inhibited by doxorubicin but suggests that there are striking
differences in their relative sensitivity to the drug. These
genes, which are positioned in proximity on the same chro-
mosome, are both expressed in the heart, albeit with different
chamber specificity.12 They are both activated by similar
provocative stimuli, typically those associated with cardiac
hypertrophy.13–16 They encode peptides that bind and activate
the same receptor in target tissues at the periphery, and they
display very similar physiological properties in laboratory
animals and humans. Despite these similarities, the sensitivity
of BNP gene expression to doxorubicin inhibition is much
greater than that seen with ANP. In addition, and equally
important, the latter inhibition is fully reversible with antiox-
idant intervention, whereas BNP expression is almost com-
pletely unaffected. This indicates that there is something quite
different about the mechanisms that underlie doxorubicin-
induced suppression of these 2 genes and that the pro-oxidant
hypothesis (see below), which seems to be the leading
contender at present, cannot explain all of the effects of the
drug, even at the level of transcription.
Plasma ANP and BNP levels are known to be increased in
pathophysiological states associated with cardiac hypertrophy
and failure. In fact, a number of recent studies have suggested
that measurement of plasma levels of these peptides may
prove useful in identifying the presence of early cardiac
dysfunction.29 The role of plasma NP measurements in
Figure 6. Probucol (Prob) stabilizes ANP mRNA in atrial myocytes. Cells were exposed to 5 mg/L Act D, with or without 20 mmol/L
Prob, for indicated time intervals. BNP and ANP transcript levels were detected by Northern blot analysis as described in Figure 2.
Representative experiments are provided in A. Pooled data from 4 independent experiments are shown in B. In separate experiments,
cells were treated with 5 mg/L Act D and 0.3 mmol/L Dox, with or without 20 mmol/L Prob, for varying periods of time. Representative
autoradiographs are shown in C. Data from 3 independent experiments are presented in D. **P,0.05, *P,0.01 vs control; 1P,0.05,
#P,0.01 vs respective Act D alone or Act D1Dox groups.
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assessing doxorubicin toxicity is less well defined. Bauch et
al17 showed that 6 of 16 pediatric patients treated with
doxorubicin (45 mg/m2 body surface area) showed elevations
in plasma ANP levels 3 weeks after administration of the
drug. In a series of animal studies, Bernardini et al18 found
that a single dose of doxorubicin (10 mg/kg IV) in normal
female Wistar rats resulted in a significant decrease in plasma
ANP levels (compared with vehicle-injected controls) 3 to 6
hours after administration of the drug, whereas rats subjected
to a more chronic dosing regimen (3 mg/kg IV per week)
displayed a significant increase in plasma ANP levels 21 and
31 days after administration of the drug. Thus, it would
appear that the plasma ANP response to doxorubicin is
biphasic with early suppression, perhaps reflecting acute
myocyte toxicity, followed by a subsequent stimulation as
cardiac hypertrophy/failure develops. Our findings, which
show a clear reduction in ANP secretion and gene expression
after doxorubicin treatment, are compatible with the acute
response reported by Bernardini et al. The late elevation in
ANP reported by both Bausch et al and Bernardini et al
probably reflects the response of residual myocardium to the
progressive decline in cardiac function that develops as the
sequelae of the initial insult begins to accrue. The findings
presented here also indicate that doxorubicin-induced sup-
pression of BNP secretion/expression, which has not been
reported previously, could prove useful as a highly sensitive
(versus ANP) marker of acute drug toxicity.
As noted above, doxorubicin has been reported to have a
number of toxic effects on the myocardial cell. These include
pro-oxidant effects resulting in free radical generation,5,6
interference with calcium dynamics in the sarcoplasmic
reticulum and plasma membrane,4 and direct inhibition of
RNA synthesis and protein production due to intercalation in
genomic DNA.7 Whereas the latter may be primarily respon-
sible for its tumoricidal properties, free radical generation
appears to be more closely tied to its cardiac toxicity. The
myocardium is particularly vulnerable, given the limitations
of its endogenous antioxidant systems.6 Furthermore, both
ICRF, a heavy metal chelator that severely constrains iron-
dependent free radical generation in the myocardial cell, and
probucol, a hypolipidemic agent with potent antioxidant
properties, have been shown to reverse the cardiac toxicity of
the anthracycline in whole-animal9,10 and/or clinical30 studies.
The inhibitory activity of doxorubicin at the level of ANP
gene transcription appears to be tied to its pro-oxidant
properties in that both ICRF and probucol at least partially
reversed the inhibition. Nevertheless, under conditions that
completely reversed the reduction of ANP mRNA levels,
neither ICRF nor probucol effectively restored BNP gene
expression. This may suggest that the BNP gene is sensitive
to a level of oxidant stress that does not perturb ANP gene
expression in these cells or that other mechanisms, not
operative in the case of ANP, are involved in regulating levels
of the BNP transcript.
In summary, the clinical use of the anthracycline doxoru-
bicin is limited by its cardiotoxic effects. These are believed
to be related to the pro-oxidant activity of the drug in the
myocardial cell. The present study indicates that sublethal
concentrations of doxorubicin selectively suppress NP gene
expression in cultured atrial cardiac myocytes. However, expres-
sion of the ANP gene is less affected than is the expression of
the BNP gene, and suppression of the latter appears less
clearly tied to the free radical–generating properties of the
drug. Assessment of NP gene expression, particularly BNP
gene expression, could prove to be a highly sensitive marker
of doxorubicin toxicity in the acute setting.
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